Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CPB1 | P15086 | 1/20 | 0.65 |
| ▸ | CPB2 | Q96IY4 | 1/20 | 0.65 |
| ▸ | SIRT2 | Q8IXJ6 | 4/20 | 0.63 |
| ▸ | SIRT1 | Q96EB6 | 2/20 | 0.63 |
| ▸ | SIRT3 | Q9NTG7 | 2/20 | 0.63 |
| ▸ | TLR2 | O60603 | 2/20 | 0.59 |
| ▸ | SIRT5 | Q9NXA8 | 1/20 | 0.55 |
| ▸ | PTGER4 | P35408 | 2/20 | 0.54 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.54 |
| ▸ | CHRNA1 | P02708 | 2/20 | 0.54 |
| ▸ | CHRNG | P07510 | 2/20 | 0.54 |
| ▸ | CHRNB1 | P11230 | 2/20 | 0.54 |
| ▸ | CHRND | Q07001 | 2/20 | 0.54 |
| ▸ | CTSL | P07711 | 1/20 | 0.53 |
| ▸ | CTSS | P25774 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24152588 | 1.00 | CPB1 (0.65) | CPB1CPB2SIRT2SIRT1SIRT3 | |
| SCHEMBL20980386 | 0.95 | CPB1 (0.60) | CPB1CPB2SIRT2SIRT1SIRT3 | |
| SCHEMBL14642688 | 0.90 | CPB1 (0.58) | CPB1CPB2SIRT2SIRT1SIRT3 | |
| SCHEMBL14642693 | 0.90 | CPB1 (0.58) | CPB1CPB2SIRT2SIRT1SIRT3 | |
| SCHEMBL15084866 | 0.89 | SIRT2 (0.61) | CPB1CPB2SIRT2SIRT1SIRT3 | |
| SCHEMBL22055423 | 0.88 | SIRT2 (0.63) | CPB1CPB2SIRT2SIRT1SIRT3 | |
| SCHEMBL14642690 | 0.88 | SIRT2 (0.61) | SIRT2SIRT1SIRT3TLR2CTSL | |
| SCHEMBL15084702 | 0.87 | SIRT2 (0.59) | CPB1CPB2SIRT2SIRT1SIRT3 | |
| SCHEMBL16782306 | 0.87 | SIRT2 (0.66) | CPB1CPB2SIRT2SIRT1SIRT3 | |
| SCHEMBL13387692 | 0.86 | MAPT (0.58) | CPB1CPB2SIRT2SIRT1SIRT3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230250053-A1 | PROCESS FOR SYNTHESIZING TARGETING MOLECULES | BRISTOL-MYERS SQUIBB COMPANY | 2023-08-10 | — | — | US | disclosed |
| WO-2021262743-A1 | PROCESS FOR SYNTHESIZING TARGETING MOLECULES | BRISTOL-MYERS SQUIBB COMPANY (US) | 2021-12-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230250053-A1 | PROCESS FOR SYNTHESIZING TARGETING MOLECULES | RARG, RARA, RARB | CPB1 2238/4885CPB2 2752/4885SIRT2 3977/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.